MCID: GRM005
MIFTS: 47

Germ Cell Cancer

Categories: Cancer diseases, Fetal diseases, Rare diseases

Aliases & Classifications for Germ Cell Cancer

MalaCards integrated aliases for Germ Cell Cancer:

Name: Germ Cell Cancer 12 54 15
Malignant Germ Cell Tumor 52 17
Neoplasms, Germ Cell and Embryonal 43
Malignant Tumor of the Germ Cell 12
Neoplasms Germ Cell 54
Germ Cell Neoplasm 12
Germ Cell Tumour 12

Classifications:



External Ids:

Disease Ontology 12 DOID:2994
MeSH 43 D009373
NCIt 49 C3708
SNOMED-CT 67 402878003
UMLS 71 C0205851

Summaries for Germ Cell Cancer

Disease Ontology : 12 A cell type cancer that has material basis in abnormally proliferating cells derives from germ cells.

MalaCards based summary : Germ Cell Cancer, also known as malignant germ cell tumor, is related to mixed germ cell cancer and pediatric germ cell cancer. An important gene associated with Germ Cell Cancer is H19 (H19 Imprinted Maternally Expressed Transcript), and among its related pathways/superpathways are Gastric cancer and Pathways in cancer. The drugs Cisplatin and Thiotepa have been mentioned in the context of this disorder. Affiliated tissues include testis, brain and bone, and related phenotypes are endocrine/exocrine gland and digestive/alimentary

Related Diseases for Germ Cell Cancer

Diseases related to Germ Cell Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 425)
# Related Disease Score Top Affiliating Genes
1 mixed germ cell cancer 35.1 MIR371A AFP
2 pediatric germ cell cancer 34.8 SPRY4 MIR371A KITLG H19 DMRT1 AFP
3 ovarian mixed germ cell neoplasm 34.6 CGA AFP
4 testicular germ cell cancer 34.4 TERT SPRY4 MIR373 MIR372 MIR371A MIR367
5 endodermal sinus tumor 33.4 POU5F1 MIR371A AFP
6 pediatric testicular germ cell tumor 33.3 POU5F1 AFP
7 central nervous system germ cell tumor 33.2 POU5F1 AFP
8 dysgerminoma 33.1 POU5F1 MIR371A KITLG DMRT1 ALPP ALPG
9 ovarian primitive germ cell tumor 32.9 POU5F1 AFP
10 germinoma 32.8 POU5F1 MIR371A CGA ALPP AFP
11 germ cell and embryonal cancer 32.8 POU5F1 MIR373 MIR371A FGF4 AFP
12 testicular cancer 32.0 TERT SPRY4 KITLG DMRT1 CGA AR
13 seminoma 31.9 POU5F1 IGF2 ESR2 DMRT1 CGA ALPP
14 mature teratoma 31.7 POU5F1 MIR371A AFP
15 teratoma 31.6 POU5F1 H19 ESR1 DMRT1 CGA AFP
16 testicular seminoma 31.4 CGA AFP
17 embryonal carcinoma 31.3 POU5F1 MIR371A IGF2 H19 FGF4 ALPG
18 infertility 31.2 H19 ESR2 CGA AR
19 male infertility 31.1 KITLG ESR2 ESR1 DMRT1 AR
20 choriocarcinoma 31.1 IGF2 H19 CGA ALPP ALPG
21 gonadoblastoma 31.1 POU5F1 DMRT1 ALPP ALPG
22 testicular germ cell tumor 31.1 SPRY4 MIR373 MIR372 MIR371A MIR367 KITLG
23 androgen insensitivity syndrome 31.0 IGF2 CGA AR
24 cryptorchidism, unilateral or bilateral 31.0 SPRY4 POU5F1 KITLG ESR2 ESR1 DMRT1
25 malignant teratoma 31.0 POU5F1 MIR371A AFP
26 hypospadias 30.9 ESR2 ESR1 AR
27 polyembryoma 30.9 CGA AFP
28 ovarian gonadoblastoma 30.9 POU5F1 DMRT1 AFP
29 sertoli cell tumor 30.8 AR ALPP AFP
30 testicular disease 30.8 SPRY4 POU5F1 MIR371A KITLG DMRT1 CGA
31 mediastinum seminoma 30.8 ALPP AFP
32 mixed germ cell tumor 30.8 CGA AFP
33 ovarian embryonal carcinoma 30.8 POU5F1 AFP
34 central nervous system germinoma 30.8 POU5F1 ALPP
35 brain germinoma 30.8 SPRY4 POU5F1 AFP
36 spermatocytoma 30.7 MIR371A DMRT1 AFP
37 complete androgen insensitivity syndrome 30.7 IGF2 CGA AR ALPG
38 intratubular embryonal carcinoma 30.7 POU5F1 AFP
39 trophoblastic neoplasm 30.7 MIR371A H19 CGA
40 meningioma, familial 30.7 TERT MIR373 IGF2 ESR1
41 leiomyoma 30.6 IGF2 ESR2 ESR1
42 disorders of sexual development 30.6 ESR2 ESR1 DMRT1 AR AFP
43 leukemia, acute myeloid 30.6 TERT POU5F1 MIR372 MIR367 KITLG ESR1
44 wilms tumor 1 30.5 TERT MIR373 IGF2 H19 ESR1 AR
45 ovarian disease 30.5 ESR2 ESR1 CGA AR
46 pre-eclampsia 30.5 IGF2 H19 CGA AR AFP
47 ewing sarcoma 30.3 POU5F1 KITLG IGF2 CSF3
48 neuroblastoma 30.3 TERT POU5F1 IGF2 H19 ESR1 CSF3
49 esophageal cancer 30.3 TERT MIR373 IGF2 H19 FGF4 CSF3
50 ovarian cancer 30.2 TERT POU5F1 IGF2 H19 ESR2 ESR1

Graphical network of the top 20 diseases related to Germ Cell Cancer:



Diseases related to Germ Cell Cancer

Symptoms & Phenotypes for Germ Cell Cancer

MGI Mouse Phenotypes related to Germ Cell Cancer:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 9.96 AFP AR CGA DMRT1 ESR1 ESR2
2 digestive/alimentary MP:0005381 9.87 AR ESR1 ESR2 IGF2 KITLG POU5F1
3 limbs/digits/tail MP:0005371 9.7 AR ESR1 ESR2 FGF4 IGF2 KITLG
4 liver/biliary system MP:0005370 9.56 AFP AR ESR1 ESR2 IGF2 KITLG
5 reproductive system MP:0005389 9.4 AFP ALPG AR CGA DMRT1 ESR1

Drugs & Therapeutics for Germ Cell Cancer

Drugs for Germ Cell Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 244)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 4 15663-27-1 2767 441203 84093
2
Thiotepa Approved, Investigational Phase 4 52-24-4 5453
3
Lenograstim Approved, Investigational Phase 4 135968-09-1
4
Methotrexate Approved Phase 4 59-05-2, 1959-05-2 126941
5
leucovorin Approved Phase 4 58-05-9 6006 143
6
Vincristine Approved, Investigational Phase 4 57-22-7, 2068-78-2 5978
7
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
8 Vitamin B Complex Phase 4
9 Folic Acid Antagonists Phase 4
10 Folate Phase 4
11 Vitamin B9 Phase 4
12
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
13
Ofloxacin Approved Phase 3 82419-36-1 4583
14
Etoposide Approved Phase 3 33419-42-0 36462
15
Carboplatin Approved Phase 3 41575-94-4 10339178 38904 498142
16
Pembrolizumab Approved Phase 3 1374853-91-4
17
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
18
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
19
Pemetrexed Approved, Investigational Phase 3 137281-23-3, 150399-23-8 60843 446556
20
Promethazine Approved, Investigational Phase 3 60-87-7 4927
21
Diphenhydramine Approved, Investigational Phase 3 58-73-1, 147-24-0 3100
22
Oxaliplatin Approved, Investigational Phase 3 61825-94-3 43805 6857599 5310940 9887054
23
Bleomycin Approved, Investigational Phase 3 11056-06-7 5360373
24
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
25
Ifosfamide Approved Phase 3 3778-73-2 3690
26
Vinblastine Approved Phase 3 865-21-4 241903 13342
27
Estradiol Approved, Investigational, Vet_approved Phase 3 50-28-2 5757
28
Norgestimate Approved, Investigational Phase 3 35189-28-7 6540478
29
Moxifloxacin Approved, Investigational Phase 3 354812-41-2, 151096-09-2 152946
30
Ethinyl Estradiol Approved Phase 3 57-63-6 5991
31
Polyestradiol phosphate Approved Phase 3 28014-46-2
32
Histamine Approved, Investigational Phase 3 51-45-6 774
33
Cyproheptadine Approved Phase 3 129-03-3 2913
34
Tyrosine Approved, Investigational, Nutraceutical Phase 3 60-18-4 6057
35 Cytochrome P-450 Enzyme Inhibitors Phase 3
36 Tubulin Modulators Phase 3
37 Antimitotic Agents Phase 3
38 Etoposide phosphate Phase 3
39 Vitamins Phase 3
40 Histamine H2 Antagonists Phase 3
41 Podophyllotoxin Phase 3 518-28-5
42 Keratolytic Agents Phase 3
43 Albumin-Bound Paclitaxel Phase 3
44 Anti-Infective Agents Phase 3
45
Isophosphamide mustard Phase 3 0
46 Anti-Bacterial Agents Phase 3
47 Gastrointestinal Agents Phase 3
48 Neurotransmitter Agents Phase 3
49 Dermatologic Agents Phase 3
50 Estradiol 17 beta-cypionate Phase 3

Interventional clinical trials:

(show top 50) (show all 265)
# Name Status NCT ID Phase Drugs
1 SIOP CNS GCT II: Prospective Trial for the Diagnosis and Treatment of Children, Adolescents and Young Adults With Intracranial Germ Cell Tumors Unknown status NCT01424839 Phase 4 Carboplatin, Etoposide, Ifosfamide;Cisplatin, etoposide, Ifosfamide (standard);Cisplatin, Etoposide, Ifosfamide (high dose)
2 HeadStart4: Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors Clinical and Molecular Risk-Tailored Intensive and Compressed Induction Chemotherapy Followed by Consolidation With Randomization to Either Single Cycle or to Three Tandem Cycles of Marrow-Ablative Chemotherapy With Autologous Hematopoietic Progenitor Cell Rescue Recruiting NCT02875314 Phase 4 Induction;Single Cycle Intensive Chemotherapy;Tandem 3 Cycle Intensive Chemotherapy
3 Protocol for the Treatment of Extracranial Germ Cell Tumours in Children and Adolescents (GC III) Unknown status NCT00274950 Phase 3 carboplatin;cisplatin;etoposide;ifosfamide;vinblastine sulfate
4 Randomized Phase II/III Study of Taxol/Paclitaxel-BEP Versus BEP in Patients With Intermediate Prognosis Germ Cell Cancer Unknown status NCT00003643 Phase 2, Phase 3 cisplatin;etoposide;paclitaxel
5 A Study to Investigate the Efficacy and Tolerability of Two Dose Levels of Lerisetron Compared With Granisetron in Patients Receiving Radiotherapy for Stage I Seminoma Unknown status NCT00004219 Phase 3 granisetron hydrochloride;lerisetron
6 Trial of Imaging and Schedule in Seminoma Testis Unknown status NCT00589537 Phase 3
7 INTERNATIONAL RANDOMIZED STUDY FOR THE SALVAGE TREATMENT OF GERM CELL TUMOURS Unknown status NCT00002566 Phase 3 carboplatin;cisplatin;cyclophosphamide;etoposide;ifosfamide;vinblastine sulfate
8 A Phase III Study Of Reduced Therapy In The Treatment Of Children With Low And Intermediate Risk Extracranial Germ Cell Tumors Unknown status NCT00053352 Phase 3 cisplatin;etoposide
9 Randomized Double-Blind Controlled Phase III Trial of Hyperbaric Oxygen Therapy in Patients Suffering Long-Term Adverse Effects of Radiotherapy for Pelvic Cancer (HOT II) Unknown status NCT01087268 Phase 3
10 A Randomized Phase III Toxicity Study of Day 2, 3, 8, 15 Short (30 Minute) Versus Day 1, 2, 3 Long (72 Hours) Infusion Bleomycin for Patients With IGCCCG Good Prognosis Germ Cell Tumors, TE3 Completed NCT00324298 Phase 3 cisplatin;etoposide
11 A Randomized Phase III Study of Sequential High-Dose Cisplatinum/Etoposide/Ifosfamide Plus Stem Cell Support Versus BEP in Patients With Poor Prognosis Germ Cell Cancer Completed NCT00003941 Phase 3 cisplatin;etoposide;ifosfamide
12 Carboplatin in the Adjuvant Treatment of Stage I Seminoma: A Radomized Comparison of Single Agent Carboplatin With Radiotherapy in the Adjuvant Treatment of Stage I Seminoma of the Testis, Following Orchidectomy Completed NCT00003014 Phase 3 carboplatin
13 A Randomized Phase III Study of Sodium Thiosulfate for the Prevention of Cisplatin-Induced Ototoxicity in Children Completed NCT00716976 Phase 3 sodium thiosulfate
14 Phase III, Double-Blind, Placebo-Controlled, Crossover Study Evaluating Aprepitant in Combination With a 5HT3 & Dexamethasone in Patients With Germ Cell Tumors Undergoing 5 Day Cisplatin-Based Chemotherapy Regimen Completed NCT00572572 Phase 3 Aprepitant;Placebo
15 SIOP Intracranial Germ Cell Tumours Protocol Completed NCT00293358 Phase 3 carboplatin;cisplatin;etoposide phosphate;ifosfamide
16 A Randomized, Prospective Double-Blind, Placebo-Controlled Trial of Prophylactic Oral Levofloxacin Following Chemotherapy for Lymphoma and Solid Tumors Completed NCT00005590 Phase 3 levofloxacin
17 RANDOMIZED MULTIINSTITUTIONAL PHASE III TRIAL OF BEP AND HIGH DOSE CHEMOTHERAPY VERSUS BEP ALONE IN PREVIOUSLY UNTREATED PATIENTS WITH POOR RISK GERM CELL TUMORS Completed NCT00002596 Phase 3 carboplatin;cisplatin;cyclophosphamide;etoposide
18 A Randomised Trial of Surgery Plus Whole Brain Radiotherapy (WBRT) Versus Radiosurgery Plus WBRT for Solitary Brain Metastases Completed NCT00124761 Phase 3
19 A Multicenter, Prospective, Randomized Trial Comparing Paclitaxel and Carboplatin or Bleomycin, Etoposide and Cisplatin in the Treatment of Malignant Ovarian Germ Cell Tumors Recruiting NCT02429687 Phase 3 Paclitaxel;Carboplatin;Bleomycin;Etoposide;Cisplatin
20 A Randomized, Open-Label, Phase 3 Study of Pralsetinib Versus Standard of Care for First Line Treatment of RET Fusion-positive, Metastatic Non-Small Cell Lung Cancer Recruiting NCT04222972 Phase 3 Pralsetinib;Carboplatin;Cisplatin;Pemetrexed;Pembrolizumab;Gemcitabine
21 Phase 3 Accelerated BEP: A Randomised Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours Recruiting NCT02582697 Phase 3 Bleomycin (active name: Bleomycin Sulfate);Etoposide;Cisplatin;Pegylated G-CSF (Pegfilgrastim);Filgrastim
22 A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) With High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) as First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors Recruiting NCT02375204 Phase 3 paclitaxel;ifosfamide;cisplatin;pegylated G-CSF;G-CSF;carboplatin;etoposide phosphate
23 A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors Recruiting NCT03067181 Phase 3 Bleomycin;Carboplatin;Cisplatin;Etoposide;Etoposide Phosphate
24 A Single Group Trial Evaluating One Cycle of Adjuvant BEP Chemotherapy in High Risk, Stage 1 Non-seminomatous Germ Cell Tumours of the Testis (NSGCTT) Active, not recruiting NCT01726374 Phase 3 BEP(500)
25 A Risk-Adapted Strategy of the Use of Dose-Dense Chemotherapy in Patients With Poor-Prognosis Disseminated Non-Seminomatous Germ Cell Tumors Active, not recruiting NCT00104676 Phase 3 cisplatin;etoposide;ifosfamide;oxaliplatin;paclitaxel
26 A Randomized Phase III Study of Paclitaxel, Ifosfamide and Cisplatin Versus Vinblastine, Ifosfamide and Cisplatin as Second-Line Therapy for Patients With Relapsed/Resistant Germ Cell Tumors Terminated NCT00072215 Phase 3 cisplatin;ifosfamide;paclitaxel;vinblastine
27 Randomized, Double Blinded, Placebo-Controlled Trial of Antibacterial Prophylaxis for the Prevention of Bacterial Infections in the Post-Engraftment Phase After Allogeneic Hematopoeitic Stem Cell Transplantation Terminated NCT00324324 Phase 3 moxifloxacin hydrochloride;Placebo
28 Prevention of Cancer/Treatment-Related Weight Loss in Children at High Nutritional Risk Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
29 Phase II Study of Single-agent Pazopanib (Votrient®) for Patients With Relapsed or Refractory Germ-cell Tumors (GCT). Unknown status NCT01743482 Phase 2 Pazopanib
30 A Prospective Multicenter Phase II Trial of Gemcitabine, Cisplatin, and Ifosfamide (GIP) in Patients With Relapsed Non-Seminomatous Germ-Cell Tumors (NSGCT) and a Predicted Favorable Prognosis Unknown status NCT00127049 Phase 2 gemcitabine, ifosfamide, cisplatin, G-CSF
31 A Prospective Phase II Trial of Cabazitaxel in Male Patients With Chemotherapy Pre-treated Metastatic Nonseminomatous Germ-cell Tumors Unknown status NCT02115165 Phase 2 Cabazitaxel
32 Phase I/II Multicentre Trial of Salvage Chemotherapy With Gem-TIP for Relapsed Germ Cell Cancer Unknown status NCT00551122 Phase 1, Phase 2 cisplatin;gemcitabine hydrochloride;ifosfamide;paclitaxel
33 Clinical Correlative Studies In Primary Central Nervous System Germ Cell Tumors: The Third International CNS Germ Cell Tumor Study Group Protocol Unknown status NCT00025324 Phase 2 carboplatin;cyclophosphamide;etoposide;thiotepa
34 High-Dose Chemotherapy With Tandem Peripheral Blood Stem Cell (PBSC) Rescue for the Treatment of High-Risk Pediatric Solid Tumors. Unknown status NCT00179816 Phase 1, Phase 2 High-Dose Chemotherapy with Tandem PBSC Rescue.
35 Tandem High-Dose Chemotherapy (HDCT) With Peripheral-Blood Stem-Cell Rescue for Patients With Metastatic Germ-Cell Tumors Failing First-Line Treatment Unknown status NCT01172912 Phase 2 carboplatin;cisplatin;dexamethasone;etoposide;ifosfamide
36 Sorafenib (NEXAVAR) Monotherapy in Patients With Inoperable/Recurrent Germ Cell Carcinoma Refractory to Chemotherapy Unknown status NCT00772694 Phase 2 sorafenib
37 A Prospective, Multicentre Trial on the Value of 18F-FET PET in the Post-therapeutic Evaluation of Childhood Brain Tumours Unknown status NCT03216148 Phase 2
38 Phase II Study of Combined Oxaliplatin and Paclitaxel for Metastatic Germ Cell Tumors Completed NCT00611962 Phase 2 Oxaliplatin, Paclitaxel
39 A Phase II Study of Gemcitabine, Oxaliplatin, and Paclitaxel in Patients With Refractory Germ Cell Carcinoma Completed NCT00183820 Phase 2 paclitaxel, gemcitabine, and oxaliplatin
40 Phase II Study of Oxaliplatin Plus Bevacizumab Salvage Chemotherapy in Patients With Germ Cell Tumors Completed NCT00393861 Phase 2 Bevacizumab and Oxaliplatin
41 PHASE II TRIAL WITH DOCETAXEL IN PATIENTS WITH RELAPSING GERM CELL CANCER Completed NCT00002903 Phase 2 docetaxel
42 Phase II Study of Everolimus in Refractory Testicular Germ Cell Cancer. Completed NCT01466231 Phase 2 Everolimus
43 Multicenter Phase 2 Trial of ARQ 197 for Subjects With Relapsed or Refractory Germ Cell Tumors Completed NCT01055067 Phase 2 Tivantinib (ARQ 197)
44 Phase II Study of Arsenic Trioxide in Neuroblastoma and Other Pediatric Solid Tumors Completed NCT00024258 Phase 2 arsenic trioxide
45 High Dose Carboplatin, Etoposide, Cyclophosphamide and Autologous Bone Marrow Transplantation for Relapsed and Refractory Germ Cell Cancer: A Phase II Pilot Study Completed NCT00002943 Phase 2 carboplatin;cyclophosphamide;etoposide
46 Phase II Study Of Arsenic Trioxide In Patients With Refractory Germ Cell Malignancies Completed NCT00036842 Phase 2 arsenic trioxide
47 INTENSIVE CHEMOTHERAPY FOR RELAPSED OR REFRACTORY GERM CELL TUMORS EMPLOYING HIGH-DOSE CARBOPLATIN, ETOPOSIDE, AND THIOTEPA WITH AUTOLOGOUS BONE MARROW RESCUE FOR PATIENTS 15 TO 60 YEARS OF AGE Completed NCT00002508 Phase 1, Phase 2 carboplatin;etoposide
48 Prospective Open-Labeled Non Randomised Phase-II Study of SU011248 (Sunitinib) in Male Patients With Relapsed or Cisplatin-Refractory Germ Cell Cancer - A CUOG / GTCSG Cooperative Phase II Study - Completed NCT00371553 Phase 2 SU011248 (Sunitinib)
49 Randomized Phase II-Trial to Determine the Impact of Darbepoetin Alfa on the Frequency of RBC Transfusions in Patients With Metastatic "Poor Prognosis" Germ Cell Tumor Treated With High-Dose Chemotherapy (HD-VIP Regimen) Completed NCT00204633 Phase 2 Darbepoetin alfa
50 High-Dose Cisplatin, Etoposide and Bleomycin (HD-PEB) Combined With Amifostine in Children With High-Risk Malignant Germ Cell Tumors - A POG Pilot Study Completed NCT00003811 Phase 2 amifostine trihydrate;cisplatin;etoposide

Search NIH Clinical Center for Germ Cell Cancer

Cochrane evidence based reviews: neoplasms, germ cell and embryonal

Genetic Tests for Germ Cell Cancer

Anatomical Context for Germ Cell Cancer

MalaCards organs/tissues related to Germ Cell Cancer:

40
Testis, Brain, Bone, Lymph Node, Bone Marrow, Lung, Ovary

Publications for Germ Cell Cancer

Articles related to Germ Cell Cancer:

(show top 50) (show all 1242)
# Title Authors PMID Year
1
Results of retroperitoneal lymph node dissection after chemotherapy in patients with pure seminoma in the orchidectomy specimen but elevated serum alpha-fetoprotein. 61 54
19493258 2009
2
Outcome analysis for patients with elevated serum tumor markers at postchemotherapy retroperitoneal lymph node dissection. 61 54
16135481 2005
3
[Diagnosis and primary treatment of testicular tumor]. 54 61
15592706 2004
4
Early predicted time to normalization of tumor markers predicts outcome in poor-prognosis nonseminomatous germ cell tumors. 61 54
15302906 2004
5
Down-regulation of estrogen receptor beta and transcriptional coregulator SNURF/RNF4 in testicular germ cell cancer. 54 61
14644130 2003
6
Analysis of the polymorphic CAG repeat length in the androgen receptor gene in patients with testicular germ cell cancer. 54 61
12385020 2002
7
Nuclear DNA content and proliferative potential of human carcinoma in situ cells in testes of intersex children. 61 54
11374808 2001
8
HCG induced hyperthyreosis in germ cell cancer. 61 54
11326684 2000
9
Semen quality and reproductive hormones before orchiectomy in men with testicular cancer. 61 54
10071288 1999
10
FGF4 dissociates anti-tumorigenic from differentiation signals of retinoic acid in human embryonal carcinomas. 61 54
9715278 1998
11
Modified-BEP Chemotherapy in Patients With Germ-Cell Tumors Treated at a Comprehensive Cancer Center. 61
32079853 2020
12
Multiregion exome sequencing of ovarian immature teratomas reveals 2N near-diploid genomes, paucity of somatic mutations, and extensive allelic imbalances shared across mature, immature, and disseminated components. 61
31911616 2020
13
Primary Pancreatic Yolk Sac Tumor Presenting as Diffusely Enlarged Pancreas in Initial 18F-FDG PET/CT. 61
32332317 2020
14
Clinical characteristics and prognostic factors of male yolk sac tumor: a Surveillance, Epidemiology, and End Results program study. 61
32562046 2020
15
Dose-dense chemotherapy for untreated poor-prognosis and relapsed germ-cell tumours: an 18-year experience with GAMEC chemotherapy. 61
31688976 2020
16
Laparoscopic and imaging findings of growing teratoma syndrome. 61
32517427 2020
17
Increased Risk of Cardiovascular Sequelae in Survivors of Male Germ Cell Cancer. 61
32186943 2020
18
Patterns of relapse and treatment outcome after active surveillance or adjuvant carboplatin for stage I seminoma: a retrospective study of the Spanish Germ Cell Cancer Group. 61
32462393 2020
19
Management of Late Relapses After Chemotherapy in Testicular Cancer: Optimal Outcomes with Dose-intense Salvage Chemotherapy and Surgery. 61
32381397 2020
20
Venous Thromboembolism During Chemotherapy for Testicular Cancer: A Population-Based Study. 61
32387044 2020
21
Yolk sac tumor of the fourth ventricle in a 3-year-old boy: imaging features. 61
32253490 2020
22
Outcomes following surgery for primary mediastinal nonseminomatous germ cell tumors in the cisplatin era. 61
32446546 2020
23
Clinicopathological factors and prognosis analysis of 39 cases of non-gestational ovarian choriocarcinoma. 61
32185550 2020
24
An extragonadal yolk sac tumor presumed to be of postmeiotic germ cell origin by genetic zygosity analysis via single nucleotide polymorphism array. 61
31631430 2020
25
What is the optimal high-dose treatment following autologous stem cell transplantation in relapsed or refractory germ cell cancer: a retrospective comparison of high-dose ICE and high-dose CE. 61
32521917 2020
26
☆Corrigendum to "Recommendations for surveillance and follow-up of men with testicular germ cell tumors: A multidisciplinary consensus conference by the Italian Germ cell cancer Group and the Associazione Italiana di Oncologia Medica" [Crit. Rev. Oncol. Hematol. 137 (2019) (May) 154-164]. 61
31927391 2020
27
Chemotherapy intensification for first-line treatment of poor-prognosis metastatic germ cell cancer is not yet ready for prime time. 61
31999546 2020
28
Early experience with chemotherapy intensification for poor-prognosis metastatic germ cell cancer and unfavorable tumor marker decline. 61
31348750 2020
29
Germline Variants in Phosphodiesterase Genes and Genetic Predisposition to Pediatric Adrenocortical Tumors. 61
32098292 2020
30
Cardiovascular Risk Factors and Disease After Male Germ Cell Cancer. 61
31821065 2020
31
Large retroperitoneal lymphadenopathy and increased risk of venous thromboembolism in patients receiving first-line chemotherapy for metastatic germ cell tumors: A study by the global germ cell cancer group (G3). 61
31715650 2020
32
Is Testicular Germ Cell Cancer Estrogen Dependent? The Role of Endocrine Disrupting Chemicals. 61
31617897 2019
33
Acute abdominal pain in an adolescent girl with an ovarian yolk sac tumor. 61
31910193 2019
34
Antitumor and antiangiogenic activity of the novel chimeric inhibitor animacroxam in testicular germ cell cancer. 61
31583820 2019
35
Clinical management of malignant ovarian germ cell tumors: A 26-year experience in a tertiary care institution. 61
31446304 2019
36
[Knowledge and early detection of testicular germ cell cancer among adolescents and young adults]. 61
31559444 2019
37
Refinement of the Management of Germ Cell Cancer: What's Next? 61
31584840 2019
38
Evaluation of Serum Biomarkers (FGF-2, HGF, MIF and PTN) in Patients With Testicular Germ Cell Cancer. 61
31662522 2019
39
The oncogene Gankyrin is expressed in testicular cancer and contributes to cisplatin sensitivity in embryonal carcinoma cells. 61
31744479 2019
40
The prognostic impact of different tumor marker levels in nonseminomatous germ cell tumor patients with intermediate prognosis: A registry of the International Global Germ Cell Tumor Collaborative Group (G3). 61
31494007 2019
41
Treatment and Outcome of Patients with Stage IS Testicular Cancer: A Retrospective Study from the Spanish Germ Cell Cancer Group. 61
31163007 2019
42
Prognostic factors for relapse in patients with clinical stage I testicular cancer: protocol for a Danish nationwide cohort study. 61
31676661 2019
43
miR-371a-3p, miR-373-3p and miR-367-3p as Serum Biomarkers in Metastatic Testicular Germ Cell Cancers Before, During and After Chemotherapy. 61
31597402 2019
44
Dysgerminoma in a 10-Year Old with 45X/46XY Turner Syndrome Mosaicism. 61
31279777 2019
45
Predicting Gonadal Germ Cell Cancer in People with Disorders of Sex Development; Insights from Developmental Biology. 61
31658757 2019
46
Therapeutic Challenges for Cisplatin-Resistant Ovarian Germ Cell Tumors. 61
31627378 2019
47
Risk of pulmonary toxicity of bleomycin and filgrastim. 61
30319063 2019
48
Novel heterozygous mutation in the PTEN gene associated with ovarian germ cell tumor complicated by growing teratoma syndrome and overgrowth in a two-year-old female. 61
31038288 2019
49
Noncaseating granulomatous diseases in germ cell cancer patients-A single-center experience. 61
31053525 2019
50
Phase II study of avelumab in multiple relapsed/refractory germ cell cancer. 61
31152292 2019

Variations for Germ Cell Cancer

Expression for Germ Cell Cancer

Search GEO for disease gene expression data for Germ Cell Cancer.

Pathways for Germ Cell Cancer

GO Terms for Germ Cell Cancer

Biological processes related to Germ Cell Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 9.86 POU5F1 IGF2 FGF4 ESR1 DMRT1 CSF3
2 gene silencing by miRNA GO:0035195 9.8 MIR373 MIR372 MIR371A MIR367 H19
3 negative regulation of transcription by RNA polymerase II GO:0000122 9.8 POU5F1 IGF2 ESR2 ESR1 DMRT1 AR
4 positive regulation of DNA-binding transcription factor activity GO:0051091 9.63 ESR2 ESR1 CSF3
5 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.54 KITLG IGF2 CSF3
6 male gonad development GO:0008584 9.46 KITLG ESR1 DMRT1 AR
7 mammary gland alveolus development GO:0060749 9.43 ESR1 AR
8 positive regulation of protein kinase B signaling GO:0051897 9.35 KITLG IGF2 FGF4 ESR1 CSF3
9 positive regulation of cell proliferation GO:0008284 9.17 MIR372 KITLG IGF2 FGF4 CSF3 CGA

Molecular functions related to Germ Cell Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 steroid hormone receptor activity GO:0003707 9.58 ESR2 ESR1 AR
2 repressing transcription factor binding GO:0070491 9.54 ESR2 ESR1 AR
3 growth factor activity GO:0008083 9.46 KITLG IGF2 FGF4 CSF3
4 alkaline phosphatase activity GO:0004035 9.43 ALPP ALPG
5 nuclear receptor activity GO:0004879 9.43 ESR2 ESR1 AR
6 estrogen receptor activity GO:0030284 9.32 ESR2 ESR1
7 estrogen response element binding GO:0034056 8.96 ESR2 ESR1
8 steroid binding GO:0005496 8.8 ESR2 ESR1 AR

Sources for Germ Cell Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....